Specialty chemicals & CDMO maker serving pharma, agro, nutrition, cosmetics and semiconductor customers globally.
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 0 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 0 | 1.9k | 2.4k | 2.6k | 2.7k | 2.9k | 3.0k | 3.1k |
| Borrowings | 0 | 556 | 238 | 407 | 740 | 764 | 806 | 792 |
| Other Liabilities | 0 | 888 | 1.1k | 1.2k | 1.2k | 1.3k | 1.4k | 1.6k |
| Total Liabilities | 0 | 3.4k | 3.8k | 4.2k | 4.7k | 5.0k | 5.3k | 5.5k |
| AssetsFixed Assets | 0 | 1.8k | 1.8k | 1.8k | 2.5k | 2.6k | 2.6k | 3.2k |
| CWIP | 0 | 65 | 174 | 525 | 331 | 525 | 633 | 154 |
| Investments | 0 | 50 | 6 | 8 | 15 | 37 | 26 | 33 |
| Other Assets | 0 | 1.4k | 1.8k | 1.9k | 1.8k | 1.9k | 2.0k | 2.1k |
| Total Assets | 0 | 3.4k | 3.8k | 4.2k | 4.7k | 5.0k | 5.3k | 5.5k |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 0 | 112 | 453 | 462 | 430 | 508 | 524 |
| Cash from Investing | 0 | 33 | -71 | -469 | -568 | -389 | -276 |
| Cash from Financing | 0 | -72 | -418 | 42 | 144 | -129 | -155 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | 0 | 85 | 225 | -16 | -136 | 156 | 235 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (39.4×) and current (38.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -3.4% growth and a 38× exit, ₹739 only delivers your return if you pay ₹250. The price is currently baking in 18% growth.
EPS grows -3.4%/yr for 5 years, then fades to 6% over 2, exits at 38×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -3.4% | 18.71 |
| FY28 | -3.4% | 18.08 |
| FY29 | -3.4% | 17.46 |
| FY30 | -3.4% | 16.87 |
| FY31 | -3.4% | 16.29 |
| FY32 | 1.3% ·fade | 16.51 |
| FY33 | 6.0% ·fade | 17.50 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.